Silence Therapeutics Plc (SLN)
13.30
-0.25
(-1.85%)
USD |
NASDAQ |
Sep 10, 16:00
13.30
0.00 (0.00%)
After-Hours: 20:00
Silence Therapeutics Enterprise Value : 568.25M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 568.25M |
| September 08, 2026 | 574.86M |
| September 04, 2026 | 617.38M |
| September 03, 2026 | 626.83M |
| September 02, 2026 | 626.83M |
| September 01, 2026 | 624.47M |
| August 31, 2026 | 567.30M |
| August 28, 2026 | 562.10M |
| August 27, 2026 | 563.52M |
| August 26, 2026 | 567.30M |
| August 25, 2026 | 573.92M |
| August 24, 2026 | 555.96M |
| August 21, 2026 | 555.02M |
| August 20, 2026 | 550.29M |
| August 19, 2026 | 571.08M |
| August 18, 2026 | 594.23M |
| August 17, 2026 | 606.04M |
| August 14, 2026 | 576.28M |
| August 13, 2026 | 588.09M |
| August 12, 2026 | 569.66M |
| August 11, 2026 | 623.52M |
| August 10, 2026 | 657.07M |
| August 07, 2026 | 492.65M |
| August 06, 2026 | 481.79M |
| August 05, 2026 | 459.11M |
| Date | Value |
|---|---|
| August 04, 2026 | 455.80M |
| August 03, 2026 | 432.65M |
| July 31, 2026 | 423.67M |
| July 30, 2026 | 477.06M |
| July 29, 2026 | 473.75M |
| July 28, 2026 | 473.75M |
| July 27, 2026 | 498.32M |
| July 24, 2026 | 448.71M |
| July 23, 2026 | 469.03M |
| July 22, 2026 | 486.98M |
| July 21, 2026 | 440.68M |
| July 20, 2026 | 423.67M |
| July 17, 2026 | 424.15M |
| July 16, 2026 | 443.99M |
| July 15, 2026 | 421.78M |
| July 14, 2026 | 388.71M |
| July 13, 2026 | 366.98M |
| July 10, 2026 | 357.53M |
| July 09, 2026 | 393.91M |
| July 08, 2026 | 398.16M |
| July 07, 2026 | 407.61M |
| July 06, 2026 | 427.92M |
| July 02, 2026 | 418.95M |
| July 01, 2026 | 424.15M |
| June 30, 2026 | 446.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| Mereo BioPharma Group Plc | 9.620M |
| NuCana Plc | -19.09M |
| Autolus Therapeutics Plc | 705.00M |
| Compass Pathways Plc | 1.680B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.29M |
| Total Expenses (Quarterly) | 12.29M |
| EPS Diluted (Quarterly) | -0.2602 |
| Earnings Yield | -9.52% |
| Normalized Earnings Yield | -9.520 |